|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-6-1
|
|
pubmed:abstractText |
Bryostatin 1 is a natural product isolated from the marine bryozoan Bugula neritina in 1982 and is currently undergoing evaluation in a number of malignancies. Twenty-five patients with relapsed, low-grade non-Hodgkin's lymphoma or chronic lyphocytic leukemia (CLL) received bryostatin 1 by 72-h continuous infusion every 2 weeks at a dose of 120 microg/m2 per course. Patients who progressed while receiving bryostatin 1 alone could participate in a feasibility study by receiving vincristine administered by bolus i.v. injection immediately after the completion of the bryostatin 1 infusion. The dose of vincristine was escalated in groups of three patients as follows: level 1, 0.5 mg/m2; level 2, 1.0 mg/m2; and level 3, 1.4 mg/m2 with vincristine doses capped at 2.0 mg for all patients. Bryostatin 1 alone resulted in one complete remission and two partial remissions. Nine patients received sequential treatment with bryostatin 1 and vincristine. The addition of vincristine at a dose of 2 mg was feasible and caused the expected dose-related sensory neuropathy. Phenotypic analysis by flow cytometric analysis on pre- and post-bryostatin 1-treated peripheral blood lymphocytes revealed up-regulation in the coexpression of CD11c/ CD22 on CD20+ B cells in two of four CLL patients studied, which is consistent with in vitro findings of differentiation of CLL cells to a hairy cell phenotype.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:Al-KatibA MAM,
pubmed-author:DasJJ,
pubmed-author:EilenderD SDS,
pubmed-author:HulburdKK,
pubmed-author:MohammadR MRM,
pubmed-author:MurgoAA,
pubmed-author:PembertonP APA,
pubmed-author:RodriguezD HDH,
pubmed-author:ShurafaM SMS,
pubmed-author:SpadoniVV,
pubmed-author:VarterasianM LML,
pubmed-author:WallNN
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
825-8
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10741703-Adult,
pubmed-meshheading:10741703-Aged,
pubmed-meshheading:10741703-Antineoplastic Agents,
pubmed-meshheading:10741703-Bryostatins,
pubmed-meshheading:10741703-Disease Progression,
pubmed-meshheading:10741703-Fatigue,
pubmed-meshheading:10741703-Feasibility Studies,
pubmed-meshheading:10741703-Female,
pubmed-meshheading:10741703-Flow Cytometry,
pubmed-meshheading:10741703-Humans,
pubmed-meshheading:10741703-Immunophenotyping,
pubmed-meshheading:10741703-Lactones,
pubmed-meshheading:10741703-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:10741703-Lymphoma, Non-Hodgkin,
pubmed-meshheading:10741703-Macrolides,
pubmed-meshheading:10741703-Male,
pubmed-meshheading:10741703-Middle Aged,
pubmed-meshheading:10741703-Neoplasm Recurrence, Local,
pubmed-meshheading:10741703-Nervous System Diseases,
pubmed-meshheading:10741703-Pain,
pubmed-meshheading:10741703-Remission Induction,
pubmed-meshheading:10741703-Treatment Outcome,
pubmed-meshheading:10741703-Vincristine
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
|
|
pubmed:affiliation |
Karmanos Cancer Institute and Wayne State University, Detroit, Michigan 48201, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
